RxDoctor Payments Data

Marcos Szomstein, MD

Colon & Rectal Surgery · Miami, FLNPI 1497799761

Payments from drug & device makers

What this record shows

This record is dominated by education: $18,283 of the $21,530 with a category attached, or 84.9%. Intuitive Surgical accounts for 92.6% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $16,979 and has fallen 99.7% since, to $52 in 2025.

$21,530in general payments, 2019–2025

Across 89 payments — averaging $241.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$20K
  • Braintree Laboratories, Inc.$455
  • Virtual Incision Corporation$359
  • Axonics, Inc.$137
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$119
  • Medtronic$106
  • plus $408 from 12 others

What the payments were for

  • Travel & lodging$1,5807%
  • Food & beverage$1,5437%
  • Education$18,28385%
  • Gifts$1251%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,530 in reported general payments places this provider in the 75th percentile of 157 colon & rectal surgery providers in Florida.

See all colon & rectal surgery providers in Florida

Medicare billing

Part B allowed, 2024
$165,513
Medicare patients
303
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf184$29,822
LinzessLinaclotide14$7,455
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates59$3,690
ClenpiqSod Picosulf/Mag Ox/Citric Ac20$3,416
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine20$1,827
Neomycin Sulfate118$722
Hydrocortisone29$615
Dicyclomine Hcl11$315
Metronidazole120$199
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$126
Tamsulosin Hcl99$84
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$84
Gabapentin11$81
Tramadol Hcl24$70
Alprazolam11$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$455$29,822184 claims
AbbVieLinzess$20$7,45514 claims
Ferring Pharmaceuticals Inc.Clenpiq$72$3,41620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 157 colon & rectal surgery providers in Florida.

Other colon & rectal surgery in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →